Celgene Corporation (CELG) news stock charts
Celgene Corporation (CELG) Investment Summary:
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States. Its primary commercial stage products include REVLIMID (lenalidomide) for the treatment in combination with dexamethasone for multiple myeloma patients who have received at least one prior therapy, as well as for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated (MDS) with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities; and THALOMID (thalidomide) ...www.celgene.com
2,813 Employees
Founded in 1980
CELGENE CORP (CELG:NASDAQ)
LAST $64.32 USD
CHANGE TODAY -0.70 -1.08%
VOLUME 5.4M
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of CELGENE CORP (CELG)
|
OPEN
$65.79
|
PREVIOUS CLOSE
$65.02
|
|
|
DAY HIGH
$65.79
|
DAY LOW
$63.56
|
|
|
52 WEEK HIGH
03/19/10 - $65.79
|
52 WEEK LOW
04/1/09 - $36.90
|
|
|
MARKET CAP
29.6B
|
AVERAGE VOLUME 10 D
2.9M
|
|
|
EPS TTM
$1.86
|
SHARES OUTSTANDING
459.7M
|
|
|
CELG Does Not Pay Dividends
|
P/E TTM
34.6x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Final Glance: Biotechnology companies
AP Digital - 03/19/2010 5:50 PM ET
Midday Glance: Biotechnology companies
AP Digital - 03/19/2010 1:14 PM ET
Biotech industry group spent $1.9M lobbying in 4Q
AP Digital - 03/19/2010 1:04 PM ET
Early Glance: Biotechnology companies
AP Digital - 03/19/2010 10:15 AM ET
Final Glance: Biotechnology companies
AP Digital - 03/18/2010 5:48 PM ET
Key developments for CELGENE CORP (CELG)
Novartis Pharmaceuticals Corporation and Celgene Corporation Settle Patent Suit with IntelliPharmaCeutics International Inc
03/11/2010
Intellipharmaceutics International Inc. announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey with IntelliPharmaCeutics International Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR(R) (dexmethylphenidate hydrochloride).
Celgene Corporation Presents at PBM Summit, Mar-16-2010
02/23/2010
Celgene Corporation Presents at PBM Summit, Mar-16-2010. Venue: Hyatt Regency - Coconut Point, Bonita Springs, Florida, United States. Speakers: Carlos Yuraszeck, Director, Compliance & Quality Management.
Celgene Corporation Presents at Expert Regulatory Guide to Advertising, eMarketing and Promotions for the Pharmaceutical Industry, Apr-14-2010
02/17/2010
Celgene Corporation Presents at Expert Regulatory Guide to Advertising, eMarketing and Promotions for the Pharmaceutical Industry, Apr-14-2010. Venue: The Union League, 140 South Broad Street, Philadelphia, PA 19102, United States. Speakers: Beth Krewson, Regulatory Counsel.
Celgene Corporation financial resources
CELG Competitors
| Company | Last | Change |
| Cephalon Inc | $72.34 USD | +1.32 |
| CR Bard Inc | $83.82 USD | -0.43 |
| Hospira Inc | $56.66 USD | +0.51 |
| Varian Medical Systems Inc | $53.30 USD | -0.50 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | CELG | Industry Range |
| Price/Earnings | 38.7x |
|
| Price/Sales | 11.0x |
|
| Price/Book | 6.7x |
|
| Price/Cash Flow | 34.4x |
|
| TEV/Sales | 9.9x |
|
|
CELG |
||
|
CELG transactions
| Type Date |
Target |
|
Private Placement
December 22, 2009 |
PTC Therapeutics, Inc. |
|
Merger/Acquisition
December 7, 2009 |
Gloucester Pharmaceuticals, Inc. |
More Recent Financial News About Celgene Corporation
Celgene Corporation to Present at the Barclays Capital 2010 Global Healthcare Conference
2010-03-19 03:52:52
Quote: SUMMIT, N.J.--(BUSINESS WIRE)--NASDAQCELGNews)www.celgene.com.Celgene management will provide an overview of the company.www.celgene.com.This release contains certain forward-looking statements whichinvolve known and unknown risks, delays, uncertainties and other factorsnot under the Company’s control. The Company’s actual results,performance, or achievements could be materially different from thoseprojected by these forward-looking statements.The factors thatcould cause actual res...Read article
US STOCKS-Wall St dips on China concerns, but banks rise
2010-03-12 05:38:17
Keywords: United States of America,Equities,Major Breaking News,Industrial conglomerates,Industrial conglomerates (industry),Financial services - diversified,Banks (industry group),Financials,Pharmaceuticals (sub-industry),Oil and gas exploration and production,Ene
Quote: Celgene Corp
(CELG.O) shares fell 1.5 percent to $60.97. The U.S. trade deficit narrowed unexpectedly as oil imports fell
to their lowest since February 1999, but exports slipped after rising
in the eight previous months. [ID:nN11203719] Stock futures barely budged before the open following a report
showing initial jobless claims dropped by 6,000 to 462,000 in the
latest week, slightly more than the expected 460,000. In other corporate news, BP Plc (BP.L)(BP.N) will pay $7 billion
to Devon Energ...Read article
'Fast Money' Recap: Next Moves
2010-03-10 04:07:35
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, David Tong ,Fast Money Recap
Quote: He said his favorite -CelgeneCELG) -- just hit another 52-week high.Melissa Lee, the moderator of the show, said Citigroup was up 7%, on tremendous volume. Terranova said investors should get into the stock for the long term. Adami said AIGAIG) was also up and advised taking profits on the stock.Lee asked Peter Schiff, president of Euro Pacific Capital, if housing could derail the market. Schiff said the housing market is in terrible shape with the government holding it up by guaranteeing mortga...Read article
Top biotech takeout targets of 2010 -Morningstar
2010-03-10 04:07:35
Keywords: Pharmaceuticals - generic and speciality,Pharmaceuticals (sub-industry),Japan,Asia,United States of America,Pharmaceuticals - diversified,Switzerland,Western Europe,Europe,United Kingdom,Chemicals,Germany,Mergers and Acquisitions (including Changes of Own
Quote: Here are the takeout targets with market value: 1) Vertex, $8.3 billion 2) Auxilium Pharma, $1.5 billion 3) Human Genome Sciences, $5.8 billion 4) InterMune, $1.3 billion 5) Celgene, $28.3 billion 6) Exelixis, $730 million 7) Genzyme, $15.2 billion 8) Crucell, $1.7 billion 9) Elan, $4.2 billionRobert MacMillan)......Read article
UK cost body spurns Celgene rare blood cancer drug
2010-03-04 08:17:49
Keywords: Pharmaceuticals (sub-industry),Biotechnology,United States of America,United Kingdom,Western Europe,Europe,Regulation and enforcement,Healthcare,Business activities,Company News item,Economic news, EC, business/financial pages,
Quote: UK cost body spurns Celgene rare blood cancer drug
LONDON, March 4 (Reuters) - Britain's healthcare cost agency
has recommended that Celgene's (CELG.O) drug Vidaza, or
azacitidine, should not be used in the state-run health service
to treat a rare blood cancer because it is too expensive. Celgene said on Thursday it would appeal against the
negative recommendation by the National Institute for Health and
Clinical Excellence (NICE). Its drug is used to treat myelodysplastic syndromes (MDS), a
gr...Read article
UPDATE - Astellas sues OSI Pharma to block poison pill plan
2010-03-03 02:14:01
Keywords: Pharmaceuticals - generic and speciality,Pharmaceuticals (sub-industry),Japan,Asia,United States of America,Mergers and Acquisitions (including Changes of Ownership),Healthcare,Pharmaceuticals and biotechnology,Biotechnology,Business activities,Contract b
Quote: UPDATE 4-Astellas sues OSI Pharma to block poison pill plan
* Astellas sues OSI to block poison pill plan * Astellas also commences $52/share tender offer * Astellas was prepared to off $55-$57/shr last yr-suit * Roche, Pfizer, Celgene may want to look at OSI-analysts * OSI shares close up 1.3 pct at $57, above offer price(Adds OSI statement, closing share price)Lewis Krauskopf NEW YORK, March 2 (Reuters) - Japan's Astellas Pharma Inc
(4503.T) sued OSI Pharmaceuticals Inc (OSIP.O) to prevent th...Read article
Celgene Corporation to Present at Two Upcoming Investor Conferences
2010-02-25 08:24:02
Quote: SUMMIT, N.J.--(BUSINESS WIRE)--CELGNews)www.celgene.com.Celgene management will provide an overview of the company.On Wednesday, March 3, 2010, Celgene will present at the RBC CapitalMarkets 2010 Healthcare Conference at 8:00 a.m. ET.thAnnual Health Care Conference at 8:45 a.m. ET.www.celgene.com.This release contains certain forward-looking statements whichinvolve known and unknown risks, delays, uncertainties and other factorsnot under the Company’s control. The Company’s actual ...Read article
CELGENE CORP /DE/ Files SEC form 10-K, Annual Report
2010-02-22 02:45:37
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Executive Summary
Celgene Corporation and its subsidiaries (collectively "we" or "our") is a
global integrated biopharmaceutical company primarily engaged in the discovery,
development and commercialization of innovative therapies designed to treat
cancer and immune-inflammatory related diseases.
Our primary commercial stage products include REVLIMID®, THALOMID® (inclusive of
Thalido...Read article
CELGENE CORP /DE/ Files SEC form 8-K, Other Events
2010-02-15 04:30:13
Quote: CELGENE CORP /DE/Request a Trial to NEW EDGAR Online Pro
Form
8-K for
CELGENE CORP /DE/
12-Feb-2010Other EventsPrivacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incompleteness,
or delays, or for ...Read article
Loosen Up, Tightwads!
2010-02-01 01:29:23
Quote: There's similarly no good reason that large, successful biotechs like Amgen (AMGN), Gilead Sciences (GILD) and Celgene (CELG) shouldn't pay dividends. All have ample net cash.
Are there any cash-rich companies that justifiably can forgo dividends? Yes. The preeminent one is Berkshire. Warren Buffett is in a class by himself as a master investor. Cash is better in his hands than in the hands of his shareholders. That can't be said for virtually anyone else.......Read article
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
2010-01-29 03:11:22
Quote: GAAP, Celgene reported net income of $254.2 million, ordiluted earnings per share of $0.54 for the quarter ended December 31,2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million,or diluted loss per share of $0.33.Celgene posted non-GAAP net income of $971.3 million or non-GAAP dilutedearnings per share of $2.08 during 2009 as compared to non-GAAP netincome of $718.8 million and non-GAAP diluted earnings per share of$1.56 in 2008. On a GAAP basis, Celgene reported net income of $...Read article
Celgene Posts 4Q Profit, Revenue Up 21%
2010-01-29 03:11:21
Keywords: celgene, celgene earnings, celgene profits, revlimid, celgene revlimid
Quote: Celgene Corp. (CELG) posted a fourth-quarter profit Thursdayand backed its 2010 outlook on increased sales of its blood cancer drug, Revlimid.The Summit, NJ –based drug maker reported a profit of $254.2 million, or 54 cents per share, compared to a loss of $149.3million, or 33 cents per share, a year ago. Excluding items, Celgene’s profit was 62 cents per share. Revenue jumped 21% to $761 million. Sales of Revlimid rose35% to $497 million in 2009.The company also backed i...Read article
Celgene swings to fourth-quarter gain, revenue up
2010-01-29 03:11:20
Keywords: , CELG, Celgene Corporation
Quote: NEW YORK (MarketWatch) -- Celgene Corp./quotes/comstock/15*!celg/quotes/nls/celg(CELG56.80,-1.31,-2.25%) said Thursday it swung to a fourth-quarter gain of $254.2 million, or 54 cents a share, from a loss of $149.3 million, or 33 cents a share, in the year-ago period. Adjusted earnings totaled 62 cents a share for the quarter. Revenue rose to $761 million, from $628 million, as the company benefitted from global market share gains, increased duration of therapy of Revlimid and reimbursement appr...Read article
UPDATE - Celgene posts Q4 profit vs loss; sales rise
2010-01-29 03:11:19
Keywords: Pharmaceuticals (sub-industry),Health and medicine,United States of America,Corporate Results,Corporate Results Forecasts,Biotechnology,General News,Nature Society and Science,Business activities,Healthcare,Company News item,Economic news, EC, business/fi
Quote: UPDATE 2-Celgene posts Q4 profit vs loss; sales rise * Celgene posts Q4 non-GAAP EPS of 62 cents/shr * Q4 revenue up 22 pct to $758 million * Sees 2010 non-GAAP EPS $2.55 to $2.60/shr(Updates with full-year figures, 2010 Revlimid forecast) BOSTON, Jan. 28 (Reuters) - Celgene Corp (CELG.O) on
Thursday posted a fourth-quarter profit and higher sales of its
cancer drugs Revlimid and Vidaza, compared with a loss a year
ago, when it was hurt by acquisition-related costs. The company reported net earn...Read article
Celgene sees 4Q profit on sales boost, lower costs
2010-01-29 03:11:19
Quote: (AP) -- Biotech drugmaker Celgene Corp. on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs.The Summit, N.J. company earned $254.2 million, or 54 cents per share, in the quarter that ended Dec. 31. That compares with a loss of $149.3 million, or 33 cents per share, in the same quarter last year. Adjusted earnings, which typically exclude one-time items, were 62 cents per share.Revenue rose 21 pe...Read article
CELGENE CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
2010-01-29 03:11:19
Quote: ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On January 28, 2010, Celgene Corporation issued a press release announcing its
financial results for its fiscal quarter and full-year ended December 31, 2009.
A copy of this press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant
to this Item 2.02...Read article
Celgene Corporation Q4 2009 Earnings Call Transcript
2010-01-29 03:11:18
Quote: Celgene Corporation (CELG)
Q4 2009 Earnings Call Transcript
January 28, 2010 9:00 am ET
Executives
David Gryska – SVP and CFO
Sol Barer– Chairman and CEO
Bob Hugin – President and COO
Analysts
Brian Abrahams – Oppenheimer & Company
Geoff Meacham – J.P. Morgan
Steve Harr – Morgan Stanley
Yaron Werber – Citi
Geoffrey Porges – Bernstein
Chris Raymond – Robert W. Baird
Rachel McMinn – Bank of America-Merrill Lynch
Mark Schoene...Read article
Celgene Corporation to Announce Fourth Quarter and Full-Year 2009 Results on January 28, 2010
2010-01-20 01:04:02
Quote: SUMMIT, N.J.--(BUSINESS WIRE)--CELGNews)www.celgene.com.www.celgene.com.This release contains certain forward-looking statements whichinvolve known and unknown risks, delays, uncertainties and other factorsnot under the Company’s control. The Company’s actual results,performance, or achievements could be materially different from thoseprojected by these forward-looking statements.The factors thatcould cause actual results, performance, or achievements to differ fromthe forward-look...Read article
Celgene Completes Acquisition of Gloucester Pharmaceuticals
2010-01-19 04:37:35
Quote: Press ReleaseSource: Celgene CorporationOn Friday January 15, 2010, 7:30 am ESTSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:- The transaction brings to Celgene ISTODAX“There is a need for better treatment options for CTCL patients and thisacquisition enables Celgene to maximize the clinical and commercialpotential of ISTODAX through our existing infrastructure, to the benefitof patients,†said Sol J. Barer, PhD, Chairman and Chief ExecutiveOfficer of Celgene Corporation...Read article
Would you like to leave a comment about Celgene Corporation CELG
Find out what social network information about Celgene Corporation are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Celgene Corporation's Stock there is more great penny stock and market information at Realpennies